Identifying EGFR-Expressed Cells and Detecting EGFR Multi-Mutations at Single-Cell Level by Microfluidic Chip

[1]  C. Culbertson,et al.  Cellular Analysis Using Microfluidics. , 2018, Analytical chemistry.

[2]  Je-Gun Joung,et al.  Vertical Magnetic Separation of Circulating Tumor Cells for Somatic Genomic-Alteration Analysis in Lung Cancer Patients , 2016, Scientific Reports.

[3]  K. Nishio,et al.  Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients , 2016, Scientific Reports.

[4]  Dahai Ren,et al.  Multiplexed Analysis for Anti-Epidermal Growth Factor Receptor Tumor Cell Growth Inhibition Based on Quantum Dot Probes. , 2016, Analytical chemistry.

[5]  Birgit Kasch,et al.  Next Generation , 2016, Im OP.

[6]  Chwee Teck Lim,et al.  Microfluidic enrichment for the single cell analysis of circulating tumor cells , 2016, Scientific Reports.

[7]  Han Gardeniers,et al.  Microfluidic device for DNA amplification of single cancer cells isolated from whole blood by self-seeding microwells. , 2015, Lab on a chip.

[8]  Ling Xu,et al.  Single-cell codetection of metabolic activity, intracellular functional proteins, and genetic mutations from rare circulating tumor cells. , 2015, Analytical chemistry.

[9]  Sijia Lu,et al.  Uniform and accurate single-cell sequencing based on emulsion whole-genome amplification , 2015, Proceedings of the National Academy of Sciences.

[10]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Qinghua Zhou,et al.  Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[13]  L. Mazutis,et al.  Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. , 2011, Lab on a chip.

[14]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[15]  A. Gazdar,et al.  Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors , 2009, Oncogene.

[16]  T. Mok,et al.  Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non–Small Cell Lung Cancer Patients , 2009, Clinical Cancer Research.

[17]  Alona Muzikansky,et al.  First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[19]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[20]  H. Tournaye,et al.  The efficiency of magnetic-activated cell sorting and fluorescence-activated cell sorting in the decontamination of testicular cell suspensions in cancer patients. , 2007, Human reproduction.

[21]  William C Hahn,et al.  Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants , 2005, PLoS medicine.

[22]  J. Minna,et al.  EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. , 2005, Cancer research.

[23]  Daniel A. Haber,et al.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.

[24]  S. Störkel,et al.  Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[25]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[26]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[27]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[28]  Lesley Seymour,et al.  Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. , 2003, The Lancet. Oncology.

[29]  R. DePinho,et al.  Pancreatic cancer biology and genetics , 2002, Nature Reviews Cancer.

[30]  W. Cavenee,et al.  Non-isotopic silver-stained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells. , 2001, International journal of oncology.

[31]  J. Grandis,et al.  Quantitative immunohistochemical analysis of transforming growth factor‐α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck , 1996, Cancer.

[32]  L. Jin,et al.  Evaluation of 13 short tandem repeat loci for use in personal identification applications. , 1994, American journal of human genetics.

[33]  R. Hubert,et al.  Whole genome amplification from a single cell: implications for genetic analysis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Farndon,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTOR STATUS AS PREDICTOR OF EARLY RECURRENCE OF AND DEATH FROM BREAST CANCER , 1987, The Lancet.

[35]  S. Cummings,et al.  A randomized trial , 2011 .

[36]  N. Goldstein,et al.  The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[37]  S. Keyse,et al.  Tyrosine kinase inhibition: an approach to drug development. , 1995, Human & experimental toxicology.